Pull to refresh
Logo
Daily Brief
Following Why Sign Up
GSK buys cancer drugmaker Nuvalent for $10.6 billion

GSK buys cancer drugmaker Nuvalent for $10.6 billion

Money Moves

GSK's largest-ever deal closed in September, adding two late-stage lung cancer drugs as it prepares for the 2028 HIV patent cliff

September 18th, 2026: FDA ruling due on zidesamtinib

Overview

Updated Oct 8

GSK closed its $10.6 billion purchase of Nuvalent in September, netting out to about $9.4 billion in cash. Both lung cancer drugs central to the deal were still under FDA review at closing; a ruling on neladalkib is due November 27.

The buyout is GSK's largest ever and the centerpiece of CEO Luke Miels' plan to rebuild the cancer business it sold to Novartis in 2015. GSK needs the revenue before its top-selling HIV drug loses patent protection in 2028. If the FDA clears both drugs, they could launch this year.

Why it matters

Two next-generation lung cancer drugs could reach patients within months, if the FDA clears them and GSK's $10.6 billion bet pays off.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$10.6B
Deal value
All-cash purchase completed in September 2026. GSK's largest acquisition.
$124/share
Offer price
About a 40% premium over Nuvalent's prior share price.
40%
Premium paid
Nuvalent shares jumped roughly 39% on the June announcement.
$5.65B
HIV revenue at risk
2025 sales of GSK's dolutegravir drugs, which lose patent protection from 2028.
2
Late-stage drugs
Zidesamtinib and neladalkib, under FDA review. Neladalkib decision due November 27, 2026.
$9.4B
Net cash outlay
Purchase price net of cash acquired, per GSK.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Luke Miels
Luke Miels
Chief Executive Officer, GSK
Deal closed September 2026; leading GSK's push into lung cancer
 James Porter
James Porter
Chief Executive Officer, Nuvalent
Selling Nuvalent to GSK

Organizations Involved

GSK (GlaxoSmithKline)
GSK (GlaxoSmithKline)
Pharmaceutical Company
Acquirer — deal completed September 2026

British drugmaker buying Nuvalent to rebuild its cancer portfolio ahead of a 2028 HIV patent cliff.
Nuvalent
Nuvalent
Biotechnology company
Acquired by GSK, September 2026

Cambridge, Massachusetts biotech whose two lung cancer drugs are the prize in GSK's $10.6 billion deal.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulatory agency
Reviewing both drugs

The U.S. regulator whose approval decisions in late 2026 will determine whether GSK's two new drugs can be sold.

Timeline

March 2015 November 2026

6 events Latest: September 18th, 2026 · 1 month ago
Tap a bar to jump to that date

  1. FDA ruling due on neladalkib

    Upcoming Regulatory

    The FDA's target decision date for Nuvalent's ALK inhibitor, the second drug central to GSK's bet.

  2. FDA ruling due on zidesamtinib

    Latest Regulatory

    The FDA's target decision date for Nuvalent's ROS1 inhibitor, the first of the two drugs to face a verdict.

  3. GSK completes $10.6 billion acquisition of Nuvalent

    Deal

    GSK closed its tender offer for all of Nuvalent's shares, its largest deal ever. Net of cash acquired, the outlay was about $9.4 billion. Both lung cancer drugs remained under FDA review at closing.

  4. GSK agrees to buy Nuvalent for $10.6 billion

    Deal

    GSK offers $124 a share in cash, about a 40% premium. Nuvalent shares jump roughly 39%. It is GSK's largest acquisition in more than a decade.

  5. Nuvalent launches

    Corporate

    Nuvalent starts with $50 million from Deerfield Management to build kinase inhibitors that overcome cancer drug resistance.

  6. GSK exits most of oncology

    Corporate

    GSK sells the bulk of its cancer business to Novartis in an asset swap, leaving a gap it would later spend years filling.

Scenarios

1

FDA approves both Nuvalent lung cancer drugs by year-end

Likely Resolves by End of 2026

Discussed by: GSK, Fierce Biotech, UBS analysts

Both drugs hold Breakthrough Therapy status and have firm FDA decision dates in September and November. If the agency clears both, GSK can start selling them this year and begin earning back its outlay. UBS analysts expect zidesamtinib alone to reach nearly $2 billion in peak annual sales.

2

GSK completes the Nuvalent takeover by end of Q3

Deadline passed (Q3 2026)

Discussed by: GSK, SEC tender offer filings

GSK is buying Nuvalent through a cash tender offer it expects to fund within 10 business days of acceptance, subject to regulatory clearance and enough shares being tendered. An all-cash deal at a 40% premium gives shareholders little reason to hold out. The main variable is how fast antitrust review clears.

3

FDA delays or rejects at least one Nuvalent drug

Unlikely Resolves by End of 2026

Discussed by: Industry analysts tracking FDA review risk

Even drugs with strong trial data can hit a complete response letter, the FDA's term for a refusal to approve as filed. A delay or rejection on either drug would push back sales and dent the math behind GSK's $10.6 billion price. This is the main downside investors are watching.

4

A rival bidder tops GSK's offer for Nuvalent

Deadline passed (Aug 31, 2026)

Discussed by: Deal arbitrage analysts

Targeted lung cancer is a contested field where Roche and Pfizer already compete. A large drugmaker hunting for late-stage assets could counter GSK's bid, though the 40% premium and tender-offer structure make a topping bid hard. No rival offer has surfaced so far.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

December 2018

GSK buys Tesaro (2018)

GSK paid $5.1 billion for Tesaro, a Massachusetts cancer biotech, to re-enter oncology three years after selling most of that business to Novartis. The deal centered on Zejula, an ovarian cancer drug. Investors initially questioned the price.

Then

GSK shares fell on the announcement as analysts called the price steep for a single lead drug.

Now

The deal anchored GSK's return to cancer drugs and set the template for buying late-stage assets rather than building from scratch.

Why this matters now

Nuvalent is the same playbook at twice the scale: buy a Massachusetts oncology biotech with near-market drugs to rebuild a portfolio GSK once walked away from.

January 2019

Eli Lilly buys Loxo Oncology (2019)

Eli Lilly paid $8 billion for Loxo Oncology, a biotech making precision drugs that target specific cancer-causing mutations rather than tumor location. The price was a 68% premium. Loxo's drugs worked across cancer types defined by genetics.

Then

The deal gave Lilly an instant precision-oncology franchise and a marketed drug, larotrectinib.

Now

It validated paying large premiums for mutation-targeted cancer biotechs, a category Nuvalent also occupies.

Why this matters now

Like Loxo, Nuvalent designs drugs aimed at precise genetic targets. Big drugmakers keep paying steep premiums for that approach, which is exactly what GSK just did.

November 2011

Pfizer's Lipitor patent cliff (2011)

Pfizer's cholesterol drug Lipitor, then the best-selling medicine ever at over $9 billion a year, lost U.S. patent protection. Generic copies flooded in within weeks. Pfizer's revenue dropped sharply and it spent years restructuring and buying replacements.

Then

Lipitor sales collapsed as cheaper generics took the market almost immediately.

Now

The episode became the textbook case of a patent cliff and pushed drugmakers to plan replacements years ahead.

Why this matters now

GSK faces its own cliff in 2028 as its $5.65 billion HIV franchise loses protection. The Nuvalent deal is GSK trying to line up replacement revenue before that drop hits.

Sources

(10)
+4
GSK CNBC STAT News Fierce Biotech SEC EDGAR GSK Reuters The Guardian SEC EDGAR Reuters